# Step 156 — PC07.01 owner acceptance and evidence consolidation

2026-10-23. **Step 155 controlled functional smoke retained: 7 real-browser groups PASS / 0 FAIL. Three owner wording/layout decisions remain PENDING. Mobile compliance visual acceptance remains QUALIFIED. PC07.01 PARTIAL; inventory unchanged: 10 mandatory-gap IDs / three packages.** Documentation consolidation only; no owner decision inferred or clinical action performed.

## 1. Scope and controlling evidence

Read AGENTS.md and relevant portions of reports [203/Step 136](203-step136-pc07-01-consolidated-gap-assessment-implementation-plan.md), [204/137](204-step137-pc07-01-clinical-source-contract-resolution.md), [205/138](205-step138-pc07-01-coordinated-implementation-focused-regression.md), [206/139](206-step139-pc07-01-deployment-readiness-manual-acceptance.md), [208/141](208-step141-pc07-01-acceptance-closure-next-implementation-scope.md), [209/142](209-step142-pc07-01-compliance-authority-interval-contract.md), [210/143](210-step143-pc07-01-compliance-authority-interval-implementation.md), [211/144](211-step144-pc07-01-integrated-acceptance-readiness.md), [221/154](221-step154-browser-unicode-transport-verification.md) and [222/155](222-step155-pc07-01-gate2-clinical-smoke-results.md). Earlier reports supply requirement definitions and qualified closures; later reports supersede only their specifically completed deployment/acceptance blockers.

Read-only inspection of existing chart links and directly relevant prescription, medication and allergy Razor views supplied navigation/wording below. Git status showed reports 217–222 untracked; preserved all existing work. Only this report added. No login, browser launch, SQL/database access, clinical request/write, code/helper edit, migration, service restart, build, test rerun or Git mutation/remote operation. No source/version research or 92-unit reassessment repeated.

## 2. Consolidated verified functionality

| Area | Retained evidence and exact disposition |
|---|---|
| Step 138 native facts | Technical PASS for separate native prescriber first/last/OHIP snapshots; independent plan long-term intent, discontinued-plan Past indicator, order Treatment type and Substitution prohibited; deliberate allergy drug applicability and DIN reconciliation. Owner wording/layout remains pending. Do not classify these as missing implementation |
| Drug Description DE09.004 | **SATISFIED — VERIFIED, qualified native contract**, per Step 141 and four prior owner PASS observations. No repeat of 300/301, compound, brand/private-note or lifecycle acceptance requested |
| Compliance DE09.018 | Step 143 implementation plus Step 155 real-tenant Compliant save and Unknown revision PASS. First supplied instant `2026-10-23T12:00:00-04:00`; revised instant NULL. Both explanations/revisions retained; assessor 2 and separate server-recorded timestamps. Live persistence blocker completed; subjective wording decision pending |
| Paper DE09.027 | Restricted native **Yes / Not recorded** implementation and live save/reload/clear PASS. No No declaration or independently authoritative electronic prescribing claim. Wider authority capability remains qualified/incomplete |
| Interval DE09.028 | Positive whole-day contract implemented; live 7-day save/reload and explicit NULL clear PASS. Native 0/-1/1.5 validation observed without submission. Independent of days' supply/repeats; subjective wording decision pending |
| Real browser integration | Step 155: **7 groups PASS / 0 FAIL**, 14 retained detailed observations; ONE normal login, four clinical submissions: two plan and two Draft saves. Both viewport widths exercised. No mocked transport. Do not add prior overlapping runs to these counts |
| SQL/audit/actor/RowVersion | Step 155 scoped SQL snapshots confirm correct tenant/patient, exact facts, two retained compliance revisions and actor 2. Medication mutation audit IDs 1028/1032; Draft audit IDs 1045/1062. Tokens progressed only on affected records; unrelated selected fields preserved. Two additional blank-note processing audits report ContentChanged=false and no note/revision creation; governed read audits retained |
| Finalized immutability | Complete finalized row, RowVersion and stored artifact unchanged before/after; real desktop/mobile read-only rendering PASS. No finalized write probe required to repeat that preservation proof |
| Deployment/recovery/transport prerequisites | Step 149 verified backup and Step 155 availability checkpoint retained. Step 154 publisher/Chromium/result path passed; Step 155 reused it unchanged. Earlier helper failures and old pending live-smoke status are historical, not current blockers. No new restore or disaster-recovery proof inferred |

The synthetic record context remains `local-dev-fresh`, patient `9f65d4ca-c347-406a-bb32-c709a8941f80`. Report 222 contains the exact record IDs, mutations, SQL versions, dates and evidence paths. This report reuses those observations; it does not attest a new live session or current database state.

## 3. Compact owner acceptance checklist — three decisions only

These are **wording/layout observations**, not another functional test matrix. Review in an already authorized owner session when available; this documentation task performs or authorizes no login or save. Open existing screens only, close editors without saving, and reuse existing screenshots for prior Yes/7/history examples. Record **PASS / FAIL**, date, viewport and one short comment per row. Use **PENDING** while unreviewed or **DEFERRED** with a reason if an appropriate screen cannot be accessed; neither is PASS.

Base application: `https://localhost:7002`. Chart navigation for the known synthetic patient:

- Medication/prescription tab: `/Patients/Details?patientUid=9f65d4ca-c347-406a-bb32-c709a8941f80&tab=medications`.
- Allergy tab: `/Patients/Details?patientUid=9f65d4ca-c347-406a-bb32-c709a8941f80&tab=allergies`.

| Owner decision | Exact existing navigation / screen | Expected wording and specific decision criterion | Current decision |
|---|---|---|---|
| **Prescription wording/layout** | Chart → **Medications** → **Prescriptions** → approved Draft row **Details**. Direct: `/PatientPrescriptions/Detail?patientUid=9f65d4ca-c347-406a-bb32-c709a8941f80&prescriptionUid=ffd80110-e565-46de-b660-3d3f9dc7e463`. **Edit draft** opens the existing Draft editor; direct route substitutes `/Edit` for `/Detail`. Finalized read-only comparator uses prescription UID `f8ccb7b2-7462-4f18-9ddd-cfddd3f234d8` on `/Detail` | Separate **Product/Brand Name**, **Drug Description**, **Prescriber first name**, **Last name**, **OHIP Billing Number**, **Treatment type**, **Substitution prohibited**, **Paper copy required before dispensing**, **Minimum dispense interval**. Editor says **Minimum dispense interval (whole days)**. Paper offers only Yes/Not recorded; unknown identity/facts remain Not recorded. PASS if the owner finds the distinct meanings and layout clear/readable at the reviewed width, understands that paper Not recorded asserts no electronic authority and interval is independent of supply/repeats. FAIL for misleading conflation, unclear units/unknown meaning, or unreadable/clipped labels/help. Do not fail historical unknown prescriber snapshots merely because they remain Not recorded | **PENDING** |
| **Medication Plan wording/layout** | Same chart tab → existing medication row **Open** → `/PatientMedications/Details?medicationUid=2521d27e-172f-47a1-9326-72eea8b0f571`. Existing row **Edit** opens the chart modal; standalone editor `/PatientMedications/Edit?medicationUid=2521d27e-172f-47a1-9326-72eea8b0f571`. Expand **Compliance assessment history** on Details; no save | **Long-term treatment intent** Yes/No/Unknown is separate from **Classification** Ongoing/Acute/Unclassified / unknown; **Past medication (discontinued plan)** means an explicitly Discontinued plan. **Medication compliance assessment**, **Assessment time**, **Assessor**, **Recorded UTC**, retained revision headings are distinct. States: Compliant / Not compliant / Unknown / Not assessed / Not recorded. PASS if owner understands these distinctions, optional assessment time versus server-recorded time, and current/revised values are readable. FAIL for clinical ambiguity or unusable wording/placement. Mobile sidebar qualification in section 4 remains separate; do not approve mobile layout from desktop alone | **PENDING** |
| **Allergy wording/layout** | Chart → **Allergies** → an existing row **Open** for Details, then that row **Edit** for applicability/help. Exact route patterns generated by existing row links: `/PatientAllergies/Details?allergyUid={existing-row-UID}&patientUid=9f65d4ca-c347-406a-bb32-c709a8941f80` and `/PatientAllergies/Edit?allergyUid={same-UID}&patientUid=9f65d4ca-c347-406a-bb32-c709a8941f80`. Use the actual row-generated UID; Step 155 identifies no allergy fixture, so none is invented here | Editor **Drug applicability (as recorded)**: Drug / Non-drug / Unknown plus separate Not recorded; **Drug DIN (confirmed drug)** and reconciliation help. Details shows **Drug applicability**, **Drug DIN**, **System entry recorded**. PASS if owner can distinguish unknown, absent and confirmed non-drug, understands DIN reconciliation and unchanged legacy type meaning, and finds labels/help readable. FAIL for conflation or unreadable/misleading presentation. Do not change applicability/DIN, resolve an allergy or alter NKA to demonstrate the text | **PENDING** |

Exact help semantics confirmed in current source:

- Prescription: “Explicit paper-view requirement only. Not recorded makes no statement of electronic authority.” Interval help states it is independent of days' supply and repeats; the 2,147,483,647 cap is technical storage, not a clinical maximum.
- Compliance: Unknown means unable to determine; Not assessed means no assessment performed; no score inferred. Blank assessment time means unknown; recorded time and assessor are separate.
- Allergy: unknown may remain blank; clear a recorded DIN deliberately before non-drug reclassification; select Drug for a confirmed drug agent; legacy type text is not automatically reclassified.

End-of-Step-155 context: Draft paper/interval are cleared; plan current assessment is Unknown with the original Compliant revision retained. Prior Yes/7 presentation is in the Step 155 screenshots. No re-entry of those facts is needed for these owner decisions.

## 4. Mobile compliance qualification — not silently PASS

Step 155 `compliance-history-390.png` retains the open sidebar after desktop-to-mobile resize, squeezing the content area and clipping sidebar labels; history continues below the captured viewport. Label/focus/visibility checks and document-horizontal-overflow assertions passed, but those assertions do not prove a satisfactory mobile layout. Prescription mobile screenshots are separate evidence and do not close this qualification.

**Disposition: QUALIFIED / mobile owner decision still pending.** No fresh reproduction or product defect attribution performed. A focused future **no-write** review can compare direct mobile entry with resize while the menu is open, then the normal closed-menu state, retaining the actual observed viewport/menu state. Do not infer a fix, blanket mobile PASS or screenshot-regression PASS without evidence/baseline. Include the owner's mobile finding within the existing Medication Plan layout decision; do not create another manual clinical test matrix.

## 5. Exact remaining PC07.01 deltas

These are subordinate requirement/source/evidence deltas, **not additional top-level inventory IDs**. Step 136's historical 92-unit totals are not recomputed after later implementations.

| Requirement / boundary | Current residual; already verified work excluded |
|---|---|
| **DE09.016/.017/.021/.022/.025/.029; allergy applicability DE11.002** | Native long-term/past mappings, original prescriber identity, treatment type, substitution prohibition and deliberate applicability are technically implemented; pending owner wording/layout above. Preserve native/source and historical-snapshot qualifications. Do not reopen already approved Q1–Q4 as missing policy |
| **DE09.018/.028; restricted .027** | Live controlled functional evidence now PASS. Remaining subjective language/layout acceptance is folded into the first two checks. Wider .027 electronic-authority/No declaration capability remains incomplete without governing semantics/authority policy; the restricted Yes/Not recorded path does not certify it |
| **DE08.008 / immunization category** | Administered dose amount + unit remains unimplemented pending approved numeric precision/domain, unit, new-entry/legacy pairing and refusal/unknown policy. DoseNumber and prescription dose do not satisfy it |
| **DE09.005** | Source-backed drug-database DIN selection/extraction/provenance and applicable uncoded/source rules remain unresolved. An arbitrary identifier pair or manual text does not prove catalogue integration |
| **DE09.030–.032** | Destination facility address/name/identifier require an approved source or entered-fact policy, association, identifier namespace and implementation/evidence. No facility master or identifier is inferred |
| **DE09.033** | Earliest pickup date/time remains dependent on approved precision, zone/offset, unknown representation and provenance; no derivation from prescription start/written date |
| **DE09.034/.035** | Coded reason and protocol reference require actual approved sources/namespaces/applicability and corresponding implementation/evidence. Indication text does not close either |
| **PC07.01(f)/.06 retrieval/audience boundary** | Separate plan/order sources and existing full-record navigation are retained. Any claim of complete required retrieval/audience coverage needs the approved field-to-owner/audience mapping; a new association or broader output requires explicit policy. No automatic name join or every-field printing requirement |
| **PC07.01(c)/PC07.04 Family M7/M8** | Residual deployed Web/permissions/state/audit and normal-session tenant-routing assertions remain evidence-only gaps. Step 155's prescription/plan login and routing are useful shared evidence but do not execute or close those Family-specific assertions |
| **External/release/source applicability** | Retain the accepted native subsets and certification-release/source qualifications recorded in reports 203/208/210. Local tests and owner wording approval cannot manufacture external authoritative source or certification acceptance |

**Not remaining implementation gaps:** qualified DE09.004 closure; accepted native allergy/NKA and DE11.008 system-entry recorded-date meaning; completed native field implementations; backup/transport prerequisites completed in their recorded scope; Step 155 clinical save/reload/audit proof. Do not recreate a separate external-original allergy recorded-date field from the resolved DE11.008 definition.

## 6. Deferred scenarios versus retained passing tests

| Scenario | Consolidated disposition |
|---|---|
| Restricted-user denial in actual development/OIDC session | **DEFERRED**: Step 155 had no approved restricted session. Step 143 API/SQL permission tests and Step 144 real Web/API/SQL 403 cases **already PASS in isolated fixtures**, but fixture authentication is not a live restricted-user login. No repeat or new grant requested |
| Optional omission-preservation save on existing Draft | **NOT EXECUTED / DEFERRED for this deployed smoke**: ordinary form supplies both fields. Step 143 omission/clear wire/API/SQL and lifecycle evidence remains PASS; no new implementation gap or mandated extra save |
| Deliberate stale-write/concurrency conflict in existing tenant | **DEFERRED**: no intentional stale mutation authorized. Step 143 stale-token/audit rollback and prescription immutable/conflict tests remain PASS; Step 155 confirms fresh reads and progression only. Do not relabel that as live conflict rejection |
| Wider electronic authority / source-dependent integrations / Family residual | Still pending within section 5, not implicitly closed by any of the above technical tests |

## 7. Inventory reconciliation — 10 distinct IDs / three packages

Use the requirement-level inventory preserved in [Step 136 section 7](203-step136-pc07-01-consolidated-gap-assessment-implementation-plan.md) and [Step 141 section 7](208-step141-pc07-01-acceptance-closure-next-implementation-scope.md). The general [current-state inventory](01-microemr-current-state-inventory.md) is a coarse module inventory, not evidence that these individual mandatory IDs have closed.

| Package | Exact counted IDs | Before | After / reason |
|---|---|---:|---|
| Prescribing | **PC04.01, PC04.06, PC04.07, PC04.09, PC04.14** | 5 | **5**; no requirement-level closure assessed here; native order improvements do not close broader parents |
| CPP | **PC07.01, PC07.04, PC07.07, PC07.10** | 4 | **4**; .01 remains partial; .04 Family residual retained; accepted Risk minimum does not independently close .07; .10 remains separately tracked encounter-managed workflow scope |
| Scheduling | **PC09.03** | 1 | **1**; untouched, no new closure evidence |
| **Total** | **10 distinct top-level mandatory-gap IDs** | **10 / 3 packages** | **10 / 3 packages** |

No new inventory IDs are added for these three owner checks, data elements, deferred scenarios or mobile qualification. No top-level count reduction, aggregate coverage recount or whole-PC07.01 SATISFIED claim is justified.

## 8. Proposed Step 157 and stop

Obtain and record the **three** compact owner decisions in section 3, with the separate mobile/menu qualification explicit. No new clinical saves, lifecycle replay, denial/stale mutation or broad suite is necessary. If a screen is unavailable, record DEFERRED rather than inventing a fixture or result.

Then select one remaining requirement-level work package from section 5 with explicit scope: obtain the still-missing administered-dose or reference/pickup/source policies, or separately authorize only the residual Family deployed-evidence work. Owner wording PASS alone cannot close those deltas or reduce the inventory. Any confirmed mobile defect needs its own bounded implementation authorization; none is performed here.

**PC07.01 PARTIAL. Inventory before → after: 10 mandatory-gap IDs / three packages → 10 mandatory-gap IDs / three packages.** Reused technical results retain their original scope and qualifications; all three owner decisions remain PENDING. Only this report added. Stop after documentation.
